PUBLICAÇÕES científicas

/cun/pt/investigacion/publicaciones-cientificas/areaMain/02
  • Gene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status

    Dueñas M (1,2,3), Pérez-Figueroa A (4), Oliveira C (5), Suárez-Cabrera C (1,2,3), Sousa A (5), Oliveira P (5), Villacampa F (2,3,6), Paramio JM (7,8,9), Martínez-Fernández M (10,11,12,13).

    (1) Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain.
    (2) Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Córdoba s/n, 28041, Madrid, Spain.
    (3) CIBERONC, Biomedical Research Networking Centers, Madrid, Spain.
    (4) Phylogenomics Lab. Department of Biochemistry, Genetics an Immunology & Biomedical Research Center (CINBIO), University of Vigo, 36310, Vigo, Spain.
    (5) Expression Regulation in Cancer Lab, Universidade do Porto, i3s & IPATIMUP. Rua Alfredo Allen, 208, 4200-135, Porto, Portugal.
    (6) Urology Department, Clinica Universidad de Navarra, Madrid, Spain.
    (7) Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain.
    (8) Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Córdoba s/n, 28041, Madrid, Spain.
    (9) CIBERONC, Biomedical Research Networking Centers, Madrid, Spain.
    (10) Molecular Oncology Unit, CIEMAT, Avda Complutense 40, 28040, Madrid, Spain.
    (11) Biomedical Research Institute, Hospital Universitario 12 de Octubre, Avda Córdoba s/n, 28041, Madrid, Spain.
    (12) CIBERONC, Biomedical Research Networking Centers, Madrid, Spain.
    (13) Genomes and Disease Lab. Center for Molecular Medicine and Chronic Diseases Research (CIMUS), Universidade de Santiago de Compostela (USC), Avda de Barcelona, 31, 15706, Santiago de Compostela, Spain.

    Scientific Reports 17 de JULHO de 2019

  • GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer

    Perez-Fidalgo JA (1,1), Iglesias M (2,2), Bohn U (3,3), Calvo E (4,4), Garcia Y (5,5), Guerra E (6,6), Manso L (7,7), Santaballa A (8,8), Gonzalez-Martin A (9,9).

    (1) Department of Medical Oncology, Hospital Clinico Universitario de Valencia, CIBERONC, Spain.
    (2) Department of Medical Oncology, Hospital Universitario Son Llatzer, Palma de Mallorca, Spain.
    (3) Department of Medical Oncology, Hospital Universitario Dr Negrin, Las Palmas de Gran Canaria, Spain.
    (4) Department of Medical Oncology, Hospital Universitario Virgen del Rocio, Sevilla, Spain.
    (5) Department of Medical Oncology, Hospital Universitario Parc Tauli, Sabadell, Spain.
    (6) Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
    (7) Department of Medical Oncology, Hospital Universitario Ramon y Cajal, Madrid, Spain.
    (8) Department of Medical Oncology, Hospital Politecnico y Universitario La Fe, Valencia, Spain.
    (9) Department of Medical Oncology, Clinica Universitaria de Navarra, Madrid, Spain.

    Future Science OA 10 de JANEIRO de 2019

  • Ghrelin Reduces TNF-α-Induced Human Hepatocyte Apoptosis, Autophagy, and Pyroptosis

    Ezquerro S (1,2), Mocha F (1), Frühbeck G (1,2,3), Guzmán-Ruiz R (2,4), Valentí V (2,5), Mugueta C (6), Becerril S (1,2), Catalán V (1,2), Gómez-Ambrosi J (1,2), Silva C (2,3), Salvador J (2,3), Colina I (7), Malagón MM (2,4), Rodríguez A (1,2).

    (1) Metabolic Research Laboratory, Clínica Universidad de Navarra, Pamplona, Spain.
    (2) CIBER Fisiopatología de la Obesidad y Nutrición, Instituto de Salud Carlos III, Madrid, Spain.
    (3) Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, Pamplona, Spain.
    (4) Department of Cell Biology, Physiology, and Immunology, Instituto Maimónides de Investigación Biomédica, University of Córdoba, Reina Sofía University Hospital, Córdoba, Spain.
    (5) Department of Surgery, Clínica Universidad de Navarra, Pamplona, Spain.
    (6) Department of Biochemistry, Clínica Universidad de Navarra, Pamplona, Spain.
    (7) Department of Internal Medicine, Clínica Universidad de Navarra, Pamplona, Spain.

    The Journal of Clinical Endocrinology and Metabolism 01 de JANEIRO de 2019

  • Generation of four Isl1 reporter iPSC lines from cardiac and tail-tip fibroblasts derived from Ai6IslCre mouse

    Linares J (1), López-Muneta L (1), Arellano-Viera E (1), Ripalda-Cemboráin P (2), Iglesias E (1), Abizanda G (3), Aranguren XL (1), Prósper F (3), Carvajal-Vergara X (4).

    (1) Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (2) Laboratory of Experimental Orthopaedics, Clínica Universidad de Navarra, Pamplona, Spain.
    (3) Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain; Cell Therapy Area, Clínica Universidad de Navarra, University of Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.
    (4) Cell Therapy Program, Center for Applied Medical Research (CIMA), University of Navarra, Instituto de Investigación Sanitaria de Navarra, Pamplona, Spain.

    Stem Cell Research 01 de DEZEMBRO de 2018

  • Gentamicin delivery to the inner ear: Does endolymphatic hydrops matter?

    Marques P (1,2), Duan M (3,4), Perez-Fernandez N (5), Spratley J (1,2,6).

    (1) Department of Otorhinolaryngology, S.João Hospital Centre, Porto, Portugal.
    (2) Unit of Otorhinolaryngology, Department of Surgery and Physiology, University of Porto Medical School, Porto, Portugal.
    (3) Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden.
    (4) Department of Otolaryngology, Head and Neck Surgery, Karolinska Universisty Hospital, Karolinska Institutet, Stockholm, Sweden.
    (5) Department of Otorhinolaryngology, Clinica Universidad de Navarra, Madrid, Spain.
    (6) Center for Health Technology and Services Research (CINTESIS), University of Porto Medical School, Porto, Portugal.

    PLoS One 15 de NOVEMBRO de 2018

talvezlhe interesse

QUE TECNOLOGIA UTILIZAMOS? 

A Clínica é o hospital privado com maiores recursos tecnológicos de Espanha, tudo num único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OS NOSSOS
PROFISSIONAIS

Os profissionais da Clínica realizam um trabalho contínuo de investigação e formação, sempre em benefício do paciente.

Imagen profesionales de la Clínica Universidad de Navarra

RAZÕES PARA VIR
À CLÍNICA

Conheça porque é que somos diferentes em relação a outros centros sanitários. Qualidade, rapidez, comodidade e resultados.

Imagen del edificio de la Clínica Universidad de Navarra